MRSH

Marsh & McLennan is a scaled, diversified advisor across insurance brokerage, reinsurance and consulting, with sticky client relationships and regulatory/complexity-driven demand that supports pricing power. Industry tailwinds include persistent risk complexity (cyber, climate, supply chain) and continued outsourcing of risk and benefits management. The 2026 brand transition toward “Marsh” is unlikely to change economics, but it can simplify go-to-market and reinforce a unified client value proposition.

Financially, the company remains high-quality: FY2025 revenue grew 10% and management cited 18 straight years of reported margin expansion, while Q1 2026 revenue was about $5.1B with adjusted EPS up 8% to $3.29 despite a $425M Greensill litigation charge pressuring GAAP EPS. TTM revenue is roughly $27.5B and TTM EPS about $8.0, implying a mid-to-high-teens/low-20s P/E at recent prices, which is reasonable for a low-beta compounder but leaves less room for execution slips. Leverage is meaningful (debt/equity elevated) while liquidity appears adequate (cash around $1.6B), and the dividend is modest (about $3.60 TTM, roughly ~2% yield), so the story relies on continued compounding more than payout.

Over the next 12 months, the bull case is steady underlying growth plus operating leverage as rates normalize and consulting demand holds, with management indicating full-year 2026 guidance remains unchanged. Key catalysts are improving fiduciary interest income sensitivity to rates, continued margin expansion, and potential share repurchases if cash flow stays strong. Key risks are adverse litigation outcomes (Greensill overhang), a sharper downturn that slows new business/consulting, and valuation compression if growth decelerates.

Recommendation: HOLD. The franchise quality and earnings resilience are attractive, but the current valuation and litigation/noise around GAAP earnings make the risk-reward more balanced after the strong run within its 52-week range.